The story of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, yielding billions in revenue , its intellectual property lapse created a deluge of lower-priced alternatives , significantly diminishing its market share . While specific pharmaceutical companies may seek to capitalize on r